Literature DB >> 8664134

Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension.

A Berruti1, A Piovesan, M Torta, C A Raucci, G Gorzegno, P Paccotti, L Dogliotti, A Angeli.   

Abstract

Serum bone alkaline phosphatase (BALP), serum carboxy-terminal propeptide of type I procollagen (PICP) and serum bone gla protein (BGP) as markers of bone formation, serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of collagen resorption and fasting molar ratio of urinary calcium to creatinine (CaCr) and serum parathyroid hormone (PTH) were determined in two groups of cancer patients: 48 with advanced or metastatic disease with negative bone scan and 174 with bone metastases categorised as having lytic, mixed or blastic lesions and with more or fewer than or equal to three sites involved. In patients without apparent bone involvement, bone formation markers were rarely elevated. Conversely, serum ICTP was frequently found to be supranormal, showing it to be a non-specific marker for early detection of bone metastases. As expected, values of bone formation markers progressively increased in patients with lytic, mixed and blastic lesions, but ICTP levels did not show any differences according to the types of bone appearances, confirming previous reports of elevated osteoclast activity also in patients with apparent blastic lesions. Serum PTH increased significantly in patients with lytic compared with patients with mixed and blastic appearances, paralleling the bone formation markers, but CaCr showed the opposite pattern. These data are compatible with calcium entrapment in the bone in patients with increased osteoblast activity. This so called 'bone hunger syndrome' is further confirmed by the finding that in the subgroup of blastic appearances CaCr diminished whereas both ICTP and PTH increased according to the extent of tumour load in the bone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8664134      PMCID: PMC2074561          DOI: 10.1038/bjc.1996.298

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

Review 1.  Advances in the management of Paget's disease of bone.

Authors:  D J Hosking
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Morphometric evidence for bone resorption and replacement in prostate cancer.

Authors:  N W Clarke; J McClure; N J George
Journal:  Br J Urol       Date:  1991-07

Review 3.  Clinical review 16: Parathyroid hormone-related proteins: coming of age in the 1990s.

Authors:  A F Stewart; A E Broadus
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

4.  Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation.

Authors:  J Risteli; I Elomaa; S Niemi; A Novamo; L Risteli
Journal:  Clin Chem       Date:  1993-04       Impact factor: 8.327

5.  Biochemical markers for detecting bone metastases in patients with breast cancer.

Authors:  L Moro; C Gazzarrini; D Crivellari; E Galligioni; R Talamini; B de Bernard
Journal:  Clin Chem       Date:  1993-01       Impact factor: 8.327

6.  Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment.

Authors:  M Terzolo; A Piovesan; G Osella; A Pia; G Reimondo; C Pozzi; C Raucci; M Torta; P Paccotti; A Angeli
Journal:  Calcif Tissue Int       Date:  1993-03       Impact factor: 4.333

Review 7.  Biochemical markers of bone turnover.

Authors:  P D Delmas
Journal:  J Bone Miner Res       Date:  1993-12       Impact factor: 6.741

8.  A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine.

Authors:  D A Hanson; M A Weis; A M Bollen; S L Maslan; F R Singer; D R Eyre
Journal:  J Bone Miner Res       Date:  1992-11       Impact factor: 6.741

9.  The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease.

Authors:  M Pecherstorfer; I Zimmer-Roth; T Schilling; H W Woitge; H Schmidt; G Baumgartner; D Thiébaud; H Ludwig; M J Seibel
Journal:  J Clin Endocrinol Metab       Date:  1995-01       Impact factor: 5.958

10.  Pyridinium crosslinks as markers of bone resorption in patients with breast cancer.

Authors:  C R Paterson; S P Robins; J M Horobin; P E Preece; A Cuschieri
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

View more
  11 in total

1.  Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.

Authors:  Primo N Lara; Benjamin Ely; David I Quinn; Philip C Mack; Catherine Tangen; Erik Gertz; Przemyslaw W Twardowski; Amir Goldkorn; Maha Hussain; Nicholas J Vogelzang; Ian M Thompson; Marta D Van Loan
Journal:  J Natl Cancer Inst       Date:  2014-02-24       Impact factor: 13.506

2.  The prognostic value and pathobiological significance of Glasgow microenvironment score in gastric cancer.

Authors:  Zhi-Hua Zhou; Cheng-Dong Ji; Jiang Zhu; Hua-Liang Xiao; Hai-Bin Zhao; You-Hong Cui; Xiu-Wu Bian
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-08       Impact factor: 4.553

3.  1,25-Dihydroxyvitamin D(3) regulates PTHrP expression via transcriptional, post-transcriptional and post-translational pathways.

Authors:  Vandanajay Bhatia; Ramanjaneya V Mula; Miriam Falzon
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

4.  Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.

Authors:  J Zhang; J Dai; Y Qi; D L Lin; P Smith; C Strayhorn; A Mizokami; Z Fu; J Westman; E T Keller
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 5.  Background to and management of treatment-related bone loss in prostate cancer.

Authors:  Alfredo Berruti; Marcello Tucci; Carlo Terrone; Gabriella Gorzegno; Roberto M Scarpa; Alberto Angeli; Luigi Dogliotti
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

6.  A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.

Authors:  Francesca M Buffa; Glenn D Flux; Matt J Guy; Joe M O'Sullivan; Victor R McCready; Sarah J Chittenden; David P Dearnaley
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-22       Impact factor: 9.236

7.  EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells.

Authors:  Vandanajay Bhatia; Manjit K Saini; Xiaoli Shen; Lian X Bi; Suimin Qiu; Nancy L Weigel; Miriam Falzon
Journal:  Mol Cancer Ther       Date:  2009-07-07       Impact factor: 6.261

8.  Markers of bone turnover for the management of patients with bone metastases from prostate cancer.

Authors:  P Garnero; N Buchs; J Zekri; R Rizzoli; R E Coleman; P D Delmas
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

9.  Reorganized Collagen in the Tumor Microenvironment of Gastric Cancer and Its Association with Prognosis.

Authors:  Zhi-Hua Zhou; Cheng-Dong Ji; Hua-Liang Xiao; Hai-Bin Zhao; You-Hong Cui; Xiu-Wu Bian
Journal:  J Cancer       Date:  2017-06-01       Impact factor: 4.207

10.  Molecular signaling pathways mediating osteoclastogenesis induced by prostate cancer cells.

Authors:  Shahrzad Rafiei; Svetlana V Komarova
Journal:  BMC Cancer       Date:  2013-12-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.